CAR-T showdown: new trial pits High-Tech cell therapy against standard care to stop Leukemia's return
NCT ID NCT07441291
Summary
This study is testing whether a personalized cell therapy (CAR-T) is better than standard chemotherapy at clearing tiny amounts of leftover leukemia cells in patients who have already had a stem cell transplant. The goal is to prevent the cancer from coming back. About 70 patients will be randomly assigned to receive one of the two treatments and followed for a year to see which works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.